Journal
CELL HOST & MICROBE
Volume 17, Issue 4, Pages 526-535Publisher
CELL PRESS
DOI: 10.1016/j.chom.2015.02.011
Keywords
-
Categories
Funding
- Seattle Biomedical Research Institute
- Bill and Melinda Gates Foundation [OPP10215171, OPP1041422, OPP1023643]
- Medicines for Malaria Venture (MMV)
- Bill and Melinda Gates Foundation [OPP1023643, OPP1041422] Funding Source: Bill and Melinda Gates Foundation
Ask authors/readers for more resources
Plasmodium vivax malaria is characterized by periodic relapses of symptomatic blood stage parasite infections likely initiated by activation of dormant liver stage parasites-hypnozoites. The lack of tractable P. vivax animal models constitutes an obstacle in examining P. vivax liver stage infection and drug efficacy. To overcome this obstacle, we have used human liver-chimeric (huHep) FRG KO mice as a model for P. vivax infection. FRG KO huHep mice support P. vivax sporozoite infection, liver stage development, and hypnozoite formation. We show complete P. vivax liver stage development, including maturation into infectious exo-erythrocytic merozoites as well as the formation and persistence of hypnozoites. Prophylaxis or treatment with the antimalarial primaquine can prevent and eliminate liver stage infection, respectively. Thus, P. vivaxinfected FRG KO huHep mice are a model to investigate liver stage development and dormancy and may facilitate the discovery of drugs targeting relapsing malaria.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available